MTOR and nonpapillary renal cell carcinoma: Dysregulated FDX1 in ccRCC could promote tumor progression through metabolic reprogramming and carcinogenic pathways, such as fatty acid metabolism, PI3K-AKT-mTOR signaling, and the Myc pathway.